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Abstract
This study characterized the effects of diabetes and/or ischemia on epidermal growth factor receptor, EGFR, and/or erbB2
signaling pathways on cardiac function. Isolated heart perfusion model of global ischemia was used to study the effect of
chronic inhibition or acute activation of EGFR/erbB2 signaling on cardiac function in a rat model of type-1 diabetes.
Induction of diabetes with streptozotocin impaired recovery of cardiac function (cardiac contractility and hemodynamics)
following 40 minutes of global ischemia in isolated hearts. Chronic treatment with AG825 or AG1478, selective inhibitors of
erbB2 and EGFR respectively, did not affect hyperglycemia but led to an exacerbation whereas acute administration of the
EGFR ligand, epidermal growth factor (EGF), led to an improvement in cardiac recovery in diabetic hearts. Diabetes led to
attenuated dimerization and phosphorylation of cardiac erbB2 and EGFR receptors that was associated with reduced
signaling via extracellular-signal-regulated kinase 1/2 (ERK1/2), p38 mitogen activated protein (MAP) kinase and AKT
(protein kinase B). Ischemia was also associated with reduced cardiac signaling via these molecules whereas EGF-treatment
opposed diabetes and/or ischemia induced changes in ERK1/2, p38 MAP kinase, and AKT-FOXO signaling. Losartan
treatment improved cardiac function in diabetes but also impaired EGFR phosphorylation in diabetic heart. Co-
administration of EGF rescued Losartan-mediated reduction in EGFR phosphorylation and significantly improved cardiac
recovery more than with either agent alone. EGFR/erbB2 signaling is an important cardiac survival pathway whose
activation, particularly in diabetes, ischemia or following treatment with drugs that inhibit this cascade, significantly
improves cardiac function. These findings may have clinical relevance particularly in the treatment of diabetes-induced
cardiac dysfunction.
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Introduction
Diabetes significantly increases the risk of cardiovascular disease
by 3- to 8-fold [1]. Current diabetic therapies are not sufficient to
completely prevent development of diabetes-induced end-organ
damage even if hyperglycemia is completely normalized [1]. Thus,
it is becoming clear that signal transduction changes induced
during hyperglycemia are not always reversed by current therapies
designed to lower glucose levels and will also need to be
normalized for effective treatment of diabetes complications.
However, despite recent advances [2], the exact mechanisms
leading to the development of cardiac dysfunction in diabetes and/
or after ischemic injury are not fully understood.
The epidermal growth factor receptor (EGFR) family of
receptor tyrosine kinases comprises four members: EGFR (erbB1),
EGFR2 (erbB2, Neu, HER2), EGFR3 (erbB3) and EGFR4
(erbB4). Of these EGFR is a 175-kDa glycoprotein that can be
activated by several different ligands including epidermal growth
factor (EGF), heparin-binding EGF (HB-EGF), amphiregulin and
betacellulin [3] to induce either homodimerization or hetero-
dimerization with other EGFR family members, most notably
erbB2 which is the preferred partner for dimerization. The erbB2
receptor lacks a ligand binding domain and therefore relies on
dimerization with other EGFR family members for signaling. For
example, EGF can serve as a ligand for activating EGFR and
recruitment of erbB2; alternatively neuregulins (NRG) can serve as
ligands for activating erbB4/erbB2 heterodimer signaling. Dimer-
ization of erbBs results in subsequent phosphorylation of several
downstream effector proteins including Ras, Raf, extracellular-
signal-regulated kinase 1/2 (ERK1/2), p38 mitogen activated
protein (MAP) kinase and phosphatidylinositol 3 (PI-3) kinase/
AKT (protein kinase B) pathways [3–5]. Alternatively, EGFR
transactivation can occur via G-protein coupled receptors
(GPCR), such as angiotensin II (Ang II) and endothelin [6].
In experimental diabetes, upregulation of EGFR signaling as a
result of increased gene expression and elevated receptor tyrosine
kinase (RTK) activity leads to vascular dysfunction in several
tissues and is therefore, detrimental in the vasculature whereas in
the diabetic heart EGFR may have a beneficial role [7–10]. At
least 3 out of the 4 erbB receptors, EGFR, erbB2, and erbB4, are
detected in the adult human and rodent hearts [11–13] where they
play an essential role in cardiac development during embryogen-
esis and might also be survival factors in the adult myocardium
[14–17]. In the failing heart, the expression and activity of erbB2
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39066a- nd erbB4 receptors are depressed [18,19] and signaling via erbB2/
erbB4 heterodimers appears critical for adult cardiomyocyte
survival [12,20,21]. The importance of erbB receptor signaling
in normal cardiac physiology was not fully recognized until the
unexpected and fatal cardiomyopathy reported in breast cancer
patients [22,23]. In patients receiving Trastuzamab, a monoclonal
antibody inhibitor of erbB2, cardiac toxicity was noted in about
5% of patients receiving the antibody alone but this number
increased to about 27% of patients when given in combination
with anthracyclines [23,24]. Surprisingly, cardiac toxicities were
not always noted with other types of erbB receptor blockers
implying that cardiac effects of erbB2 might be related to the
specific drug used [23,25,26]. More recently, signaling through
EGFR was shown to provide cardioprotection against stress-
induced injury, and reduction in EGFR activity impacts on
cardiomyocyte hypertrophy and survival [27].
In the non-diabetic heart, we showed that chronic inhibition of
EGFR with AG1478 attenuated the beneficial effects of cardiac
preconditioning (PC) to ischemia-reperfusion injury implying that
activation of EGFR signalling during PC is important for
improving recovery following ischemia-reperfusion (I/R) injury
[28]. However, the role of erbB receptor signaling in diabetes-
induced cardiac dysfunction is not known. Thus in this study we
sought to characterize the effects of inhibiting or activating EGFR
or erbB2 signaling on cardiac function in isolated hearts subjected
to I/R injury from normal or streptozotocin-induced diabetic rats.
FoxO transcription factors that belong to forkhead family of
transcriptional regulators have diverse cellular functions including
proliferation, apoptosis, DNA repair, autophagy and defense
against oxidative stress depending on the cellular environment and
tissue type ubiquitination [29]. In the heart, FoxO1 and FoxO3
proteins appear to be cardioprotective following oxidative stress
through regulation of anti-oxidant gene expression and additional
survival pathways [30]. The PI-3kinase/AKT pathway, down-
stream effector molecules of EGFR/erbB2 receptors, are major
regulators of FoxO activity. PI-3 kinase-mediated phosphorylation
of AKT leads to its nuclear localization and subsequent
inactivation of FoxO via nuclear export of FoxO into the cytosol
where it is degraded by ubiquitination [29]. Thus, we also sought
to determine the changes in EGFR-erbB2/Akt-FoxO survival
pathways after global ischemia and following activation of EGFR
signaling by EGF in both normal and diabetic hearts.
Methods
Animal groups and drug treatment
All animal experiments in this study were approved by the
Research Administration at Kuwait University and conformed to
their ethics guidelines for the care and use of laboratory animals
that are based on those published by the US National Institute of
Health (NIH publication No 85-23, revised 1985).
Induction of diabetes
Diabetes was induced by a single ip injection (55 mg/kg, body
weight) of streptozotocin (STZ) in male Wistar rats weighing
approximately 300 g as described previously [9,10,28]. Age-
matched controls were injected with vehicle alone. The rats had
free access to food and water throughout the study. Blood glucose
levels were determined before and 48 hrs after injection of STZ.
Rats with fasting blood glucose levels above 250 mg/dl were
considered diabetic and included in the study. In addition, glucose
levels of the rats were determined 4 weeks later prior to sacrificing
the animals as described previously [31].
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EGFR/ERBB2 Signaling in Diabetic Hearts
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39066Chronic treatments with EGFR and erbB2 inhibitors
The following animal groups were employed in this study.
Group 1: Vehicle-treated (non-diabetic) control (C) animals.
Group 2: AG825-treated control animals. Group 3: AG1478-
treated control animals. Group 4: Vehicle-treated STZ-diabetic
animals. Group 5: AG825-treated diabetic animals. Group 6:
AG1478-treated diabetic animals.
AG825 or AG1478 at a dose of 1 mg/kg, or vehicle (1% DMSO
in normal saline) was chronically administered i.p. every other day
for four weeks starting from the day of diabetes induction. The dose
of AG825 an AG1478 was selected based on our previous study in
the same model of diabetes [9,10]. N=10 animals per group.
Acute administration of EGF and/or Losartan to isolated
hearts from normal and diabetic rats
EGF (10
28 M) was infused into isolated hearts (from normal or
diabetic rats) for a period of 10 min either immediately before ischemia
(i.e. during perfusion) or for 10 min immediately after ischemia (i.e.
during reperfusion). Losartan (2 mM) was infused for 10 min after
ischemia either alone or in combination with EGF (10
28 M). The dose
of EGF was selected based on previous animal studies [27,32].
Heart perfusion studies
The excised hearts were mounted on the Langendorff perfusion
assembly (Hugo Sachs Electronics, Freiburg, Germany), and were
perfused initially with a constant-pressure-perfusion of 50 mm Hg
with oxygenated (95% O2 +5% CO2) Krebs – Henselit buffer
(37uC) of the following composition (in mM): NaCl 117; KCl 4.39;
CaCl2 2.5; NaHCO3 20.0; KH2PO4 1.21; MgCl2.6H2O 1.2;
Glucose 12.0; osmolarity 300 mOsm/l, pH 7.35. A water-filled
balloon was introduced into the left ventricle and connected to a
Statham pressure transducer (P23Db) and balloon volume was
adjusted to give the baseline end-diastolic pressure of 5 mmHg.
Perfusion pressure was measured immediately downstream from
the flow probe in a branch of the aortic cannula using a Statham
pressure transducer and was electronically maintained constant at
Figure 1. Diabetes is associated with reduced expression and phosphorylation of erbB2 receptor at multiple tyrosine sites that can
be further inhibited by chronic treatment with AG825. a) Representative Western blots showing levels of phosphorylated erbB2 at Y877,
Y1248, Y1248-a (which represents detection of Y1248 using an alternative antibody (p- erbB2-Antibody (Tyr1248)/EGFR (Tyr1173)) and Y12221/2 as
well as total erbB2 (t-erbB2) and actin as a control protein in non-diabetic control hearts (C), diabetic hearts (D) and diabetic hearts chronically treated
with AG825 (+AG825). b) quantification of erbB2 expression relative to actin and c–f) quantification of erbB2 phosphorylation at the stated tyrosine
site relative to total erbB2 expression for all the groups studied by densitometry. N=4; * significantly different from control (p,0.05); ** significantly
different from diabetes (p,0.05).
doi:10.1371/journal.pone.0039066.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e3906650 mmHg by means of a perfusion pressure control module. This
system permits accurate adjustment of perfusion pressure between
5–300 mmHg to an accuracy of 61 mmHg. Hearts were perfused
for 30 minutes and then subjected to 40 minutes of ischemia (I)
followed by a period of 30 minute reperfusion (R). Post-I/R
cardiac parameters (Left ventricular developed pressure (Pmax),
left ventricular end-diastolic pressure (LVEDP), 6dP/dT and
coronary flow (CF) parameters were continuously recorded.
ErbB receptor signaling studies
Western Blotting for total (t-) and/or phosphorylated (p-) forms
of EGFR, erbB2, ERK1/2, p38 MAP kinases, AKT and
FOXO3a were performed essentially as described by us previously
[7,8,9,33,34]. Briefly, left ventricles of isolated hearts were
dissected, snap-frozen in liquid nitrogen and stored at 280uC.
The retrieved tissue samples were defrosted in ice, lysed and
aliquots of equal protein subjected to SDS-PAGE gel electropho-
resis and transferred onto PVDF membrane. Appropriate
monoclonal and secondary antibodies (from either Upstate or
Cell Signaling, USA) were used to detect phosphorylated and/or
total forms of the desired proteins as described previously [7].
Actin was used as a loading control. Images were analysed and
quantified by densitometry. The following antibodies from Cell
Signaling (USA) were used in this study: t-EGFR-Antibody (rabbit)
Cat. No. 2232, p-EGFR-Antibody (Tyr992) (rabbit) Cat.
No. 2235, p-EGFR-Antibody (Tyr1068) (rabbit) Cat. No. 2234,
p-EGFR-Antibody (Tyr1086) (rabbit) Cat. No. 2220, p-EGFR-
Antibody (Tyr1148) (rabbit) Cat. No. 4404, t-Her2/ErbB2-Anti-
body (29D8) (rabbit) Cat. No. 2165, p-Her2/ErbB2-Antibody
(Tyr877) (rabbit) Cat. No. 2241, p-Her2/ErbB2-Antibody
(Tyr1248) (rabbit) Cat. No. 2247, p-Her2/ErbB2-Antibody
(Tyr1248)/EGFR(Tyr1173) (rabbit) Cat. No. 2244, p-Her2/
ErbB2-Antibody (Tyr1221/1222) (rabbit) Cat. No. 2243, p-
Foxo3a (Ser 253) Cat. No. 9466, p-ERK1/2 (p44/42 MAP
Kinase, Thr202/Tyr204) Antibody (rabbit) Cat. No. 9101. In
addition the following antibodies were purchased from Santa
Figure 2. Diabetes is associated with reduced expression and phosphorylation of EGFR receptor at multiple tyrosine sites that can
be further inhibited by chronic treatment with AG1478. a) Representative Western blots showing levels of phosphorylated EGFR at Y992,
Y1068, Y1086, and Y1148 as well as total EGFR (t-EGFR) and Actin as a control protein in non-diabetic control hearts (C), diabetic hearts (D) and
diabetic hearts chronically treated with AG1478 (+AG1478). b) quantification of EGFR expression relative to actin and c–f) quantification of EGFR
phosphorylation at the stated tyrosine site relative to total EGFR expression for all the groups studied by densitometry. N=4; * significantly different
from control (p,0.05); ** significantly different from diabetes (p,0.05).
doi:10.1371/journal.pone.0039066.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39066Figure 3. The effect of erbB inhbitors on phosphorylation of ERK1/2, p38 MAP kinase and AKT signaling. a) Representative Western
blots and b–d) quantification of phosphorylation for the stated molecule relative to total actin expression for all the groups studied by densitometry.
N=4; ** significantly different from diabetes (p,0.05).
doi:10.1371/journal.pone.0039066.g003
Figure 4. ErbB2/EGFR dimers are reduced in diabetes and by chronic treatment with AG1478 or AG825. Panel a) are represenatative
Western Blots following immunoprecipitations (IP) with either total-EGFR or total-erbB2 antibody and subsequent immunoblotting (IB) with both
antibodies individually. Panel b) represents the mean ratio of erbB2/EGFR dimers as assessed by densitometry for non-diabetic control hearts (C),
diabetic hearts (D) and diabetic hearts chronically treated with AG1478 (+AG1478) or AG825 (+AG825). N=4; * significantly different from control
(p,0.05); ** significantly different from diabetes (p,0.05).
doi:10.1371/journal.pone.0039066.g004
EGFR/ERBB2 Signaling in Diabetic Hearts
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39066Cruz, USA: p-Akt1/2/3 (Ser 473)-R Antibody: rabbit polyclonal
IgG Cat. No. sc-7985-R and the p-p38 (Thr 180/Tyr182)-R
rabbit polyclonal IgG K-2706 Cat. No. Sc-17852-R whereas the
Anti-Actin rabbit polyclonal IgG (1 ml/10 ml) Cat. No. A-2066
was obtained from Sigma Chemical Co, USA.
Receptor co-association immunoprecipitation studies
Anti-human EGFR (Cat. No. 2232; Cell Signaling, USA) or
anti- human erbB2 antibody (Cat. No. 2165; Cell Signaling, USA)
was added to 1 mg of tissue lysate sample at a dilution of 1:50, and
incubated on a tube rotator overnight at 4uC. Then 50 mlo f
protein A-agarose beads (Millipore, USA) was added to the
samples and incubated on a end-over-end tube rotator at 4uC for a
further 3 h. The bead pellets were then washed 3 times with excess
lysis buffer containing protease inhibitor cocktail (Sigma, USA)
(400 ml), and collected by centrifugation at the maximum speed for
5 seconds. The pellets were then resuspended in 30 ml of sample-
loading buffer and and heated to 100uC for 10 min. Samples were
subjected to SDS-PAGE electrophoresis and immnunoblotting
was performed for EGFR or erbB2 as described above.
Table 2. Effect of Epidermal Growth Factor (EGF) on post ischemic recovery in cardiac contractility and coronary flow.
Groups
studied Pmax (mmHg) LVEDP (mmHg) +dp/dt (mmHg s
21) 2dp/dt (mmHg s
21) Coronary Flow (ml min21)
Baseline REP % R Baseline REP % R Baseline REP % R Baseline REP % R Baseline REP % R
Control (C) 53682 6 645 0 62 6.860.4 16622 4 3 629 17196325 7976132 4762 216496283 2602691 3763 8.560.2 4.061.0 4667
C+ EGF (P) 85619 51665 9 63* 6.760.6 14612 1 0 643 1 4 2 6452 16316159 5364 220946411 211916152 5864* 9.861.5 4.660.4 4763
C+ EGF (R) 74653 8 625 1 63 6.360.3 16612 4 8 693 1 3 1 6154 1485684 4762 22142699 2949627 4462* 12.760.7 6.660.3 5261
Diabetes (D) 75615 10621 4 61* 6.560.4 56618 6 1 650* 30546717 287673 1061* 217916450 2231653 1361* 8.560.2 0.860.1 961*
D+ EGF (P) 115613 30632 6 62
# 7.060.3 49646 9 6 664
# 32156189 698650 2261
# 223176223 2488666 2264
# 7.660.5 2.360.6 2966
#
D+ EGF (R) 78617 27643 2 62
# 6.760.2 50617 4 6 649
# 21226137 7626196 3567
# 215616182 2479641 3162
# 9.762.5 2.661.0 2563
#
The data for Baseline was computed at 30 min perfusion period before ischemia and the data for Reperfusion (REP) was computed at 30 min reperfusion period, and
expressed as mean 6SEM (N=6); Pmax=Left ventricular developed pressure; LVEDP=Left ventricular end-diastolic pressure; +dp/dt=Positive derivative of pressure;
2dp/dt=Negative derivative of pressure; %R=% recovery=(reperfusion/baseline)6100; P=drug given during Perfusion before Ischemia; R=drug given during
Reperfusion after Ischemia;
*Value significantly different from Control, p,0.05;
# Value significantly different from Diabetes, p,0.05.
doi:10.1371/journal.pone.0039066.t002
Figure 5. A comparison of the % change in cardiac function parameters for normal (C) and diabetic (D) hearts following acute EGF
administration (+EGF) before ischemia (i.e. during perfusion (P)) or after ischemia (i.e. during reperfusion (R)). The percent change in
parameter is calculated relative to the % recovery seen in the respective non-diabetic (C) or diabetic (D) controls and plotted for a) LVEDP; b) Pmax; c)
+dp/dt; d) 2dp/dt; and e) coronary flow. * significantly different from control (p,0.05); # significantly different from diabetes (p,0.05).
doi:10.1371/journal.pone.0039066.g005
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39066Figure 6. Representative Western blots to show ischemia-induced changes in phosphorylation of EGFR and erbB2 receptors and
downstream signaling molecules for a) normal (non-diabetic) control hearts (C) and those subjected to 40 min ischemia (CI) and b)
diabetic hearts (D) and those subjected to 40 min ischemia (DI).
doi:10.1371/journal.pone.0039066.g006
Figure 7. Acute EGF treatment in non-diabetic control hearts opposes the ischemia-induced changes in phosphorylation of EGFR/
erbB2 signaling cascade. a) A representative Western blot of phosphorylation changes in key molecules following acute administration of EGF
before ischemia (CEP) or after ischemia (CER) is compared to control hearts subjected to 40 mins ischemia (CI); b–g) densitometry plots quantifying
the relative intensity of bands for the stated molecule relative to actin. N=4; * significantly different to CI.
doi:10.1371/journal.pone.0039066.g007
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Results were analyzed using Graph pad Prism software. Data are
presented as mean 6 SEM of ‘n’ number of experiments. Reperfusion
values were compared with their respective baseline controls using a
two tailed, paired t-test. Mean values were compared using analysis of
variance followed by post hoc test (Bonferroni). The difference was
considered to be significant when p value was less than 0.05.
Results
Blood Glucose levels
Induction of diabetes by STZ resulted in a significant increase
in blood glucose concentration. Hyperglycemia persisted in the
diabetic animals and was 593613 mg/dl at four weeks as
compared with 9767 mg/dl in the control animals. Blood
glucose levels were not significantly affected by chronic treatment
with AG1478 (595610 mg/dl) or AG825 (587612 mg/dl)
respectively.
Cardiac contractility and hemodynamics in diabetic
animals chronically treated with AG825 or AG1478
Table 1 shows the cardiac contractility parameters and
coronary flow in normal or diabetic hearts treated with AG1478
(a selective inhibitor of EGFR tyrosine kinase activity) or AG825 (a
selective inhibitor of erbB2 tyrosine kinase).
In isolated hearts subjected to 40 min of global ischemia
followed by 30 mins of reperfusion, 4- weeks of diabetes led to a
impaired recovery in all cardiac parameters studied compared to
non-diabetic controls (Table 1). Chronic treatment with AG1478
or AG825 markedly reduced cardiac recovery in both normal and
diabetes but the inhibitory effect appeared to be greater with
AG825 (Table 1). In normal hearts, inhibitors had a much greater
Figure 8. Acute EGF treatment in diabetic hearts opposes the diabetes and/or ischemia-induced changes in phosphorylation of
EGFR/erbB2 signaling cascade. a) A representative Western blot of phosphorylation changes in key molecules following acute administration of
EGF before ischemia (DEP) or after ischemia (DER) is compared to diabetic hearts subjected to 40 mins ischemia (DI); b–g) densitometry plots
quantifying the relative intensity of bands for the stated molecule relative to actin. N=4; * significantly different to DI.
doi:10.1371/journal.pone.0039066.g008
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39066reduction in cardiac function than in diabetes. Diabetes alone
resulted in a significant worsening of the recovery of hearts
following I/R to an average % recovery of around 10%, and
chronic treatment with AG1478 or AG825 of diabetic animals
generally led to a further worsening in cardiac function beyond
diabetes alone (Table 1).
Diabetes is associated with reduced cardiac EGFR and
erbB2 phosphorylation and attenuated downstream
signalling via ERK1/2, p38 MAP kinase and AKT
Western blotting analyses showed that hearts isolated from
STZ-induced diabetes, but not exposed to I/R, exhibited
significantly reduced phosphorylation of EGFR and erbB2 at
multiple tyrosine (Y) residues. In the case of erbB2 reduced
phosphorylation was observed at Y877, Y1248 (as detected by two
different primary antibodies) and Y1221/1222 (Figure 1) whereas
EGFR phosphorylation was reduced at Y992, Y1068, Y1086, and
Y1148 (Figure 2). Furthermore, chronic treatment of diabetic
animals with either AG1478 or AG825 resulted in a significantly
marked further inhibition in the phosphorylation of EGFR or
erbB2 respectively at all the tyrosine residues studied (Figure 1 and
2). Both AG1478 and AG825 significantly inhibited phosphory-
lation of the potential downstream effectors, ERK1/2, p38 MAP
kinase and AKT in diabetic hearts not exposed to I/R (Figure 3).
Co-association of erbB2/EGFR receptors in diabetic and
treated hearts
Immunoprecipitation studies were undertaken in all animal
groups to ascertain whether EGFR and erbB2 could be co-
precipitated – an indicator of their co-association or heterodimer-
ization. Immunopreciptation of EGFR with an a specific antibody
for EGFR resulted in co-precipitation of erbB2 and likewise, pull
down of erbB2 with an anti-erbB2 antibody showed a co-
association with EGFR (see Figure 4). The level of co-association
of the two erbB receptors was reduced in diabetic hearts compared
to normal. Also treatments with AG1478 or AG825 both reduced
the levels of co-association of the two erbB receptors though the
inhibition was greater with AG825 (see Figure 4).
Acute administration of EGF before or after ischemia
improves cardiac recovery in diabetic hearts
Acute administration of EGF, a ligand for EGFR, before
ischemia or after ischemia led to a marked and significant
improvement in cardiac contractility and coronary flow in diabetic
hearts but little or only modest improvements in the cardiac
function of normal hearts (Table 2). The effect of EGF in diabetic
hearts was greatest for CF and minimal in the case of LVEDP
(Table 2). Figure 5 highlights the relative % change in the various
cardiac parameters between normal and diabetic hearts upon EGF
administration either before or after ischemia. Administering EGF
to diabetic hearts before ischemia appeared to yield a greater
improvement in recovery of LVEDP and coronary flow whereas
administration after ischemia led to a greater improvement in
Pmax, +dp/dt, and 2dp/dt (Table 2; Figure 5).
Acute administration of EGF opposes ischemia-induced
changes in phosphorylation of EGFR, erbB2, and
signalling via ERK1/2, p38 MAP kinase, AKT and FOXO in
diabetic hearts
Phosphorylation of EGFR, erbB2, ERK1/2, p38 MAP kinase,
AKT and FOXO3a was reduced following 40 mins of ischemia in
normal and diabetic hearts (Figure 6). In contrast, EGF
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39066administration either before or after ischemia enhances phosphor-
ylation of EGFR, erbB2, ERK1/2, p38 MAP kinase, AKT and
FOXO3a proteins in both normal (Figure 7) and diabetic hearts
(Figure 8).
Combined administration of EGF with Losartan improves
cardiac recovery more than with each drug alone in
diabetic hearts
We next compared the functional recovery of diabetic hearts
treated with EGF with those treated with Losartan, an AT1
receptor blocker. EGF administration after ischemia at a
concentration of 10
28 M resulted in comparable improvement
in cardiac parameters compared with Losartan administered at a
concentration of 2610
26 M (Table 3). Further, combination
treatment of hearts with both EGF and Losartan given simulta-
neously during reperfusion significantly enhanced recovery in all
cardiac parameters more than with each drug alone (Table 3). In
the case of % recovery in CF, the EGF and Losartan combination
appeared to be additive (Table 3 and Figure 9). Combined EGF/
Losartan-mediated improvement in +dp/dt was significantly
higher than Losartan alone but not significantly different from
EGF alone (Table 3 and Figure 9c).
Since Losartan is known inhibitor of Angiotensin II-mediated
EGFR transactivation [6], we next examined the impact of
Losartan and/or EGF administration on EGFR phosphorylation
in diabetic hearts. Diabetic hearts treated with Losartan exhibited
a lower EGFR phosphorylation compared to untreated diabetes
following I/R. In contrast, combination treatment of Losartan
with EGF, attenuated the Losartan-mediated reduction in EGFR
phosphorylation where EGFR phosphorylation levels were
elevated comparable to that of EGF alone (Figure 10).
Discussion
The major novel finding of this study is that diabetes is
associated with a reduction in EGFR/erbB2 heterodimer signaling
in the heart and that activation of EGFR/erbB2 signaling via EGF
leads to markedly improved cardiac recovery from I/R by
opposing diabetes and/or ischemia induced changes in ERK1/
2, p38 MAP kinase, AKT and FOXO signaling. In the diabetic
hearts, this study showed that the relative improvements in cardiac
function with EGF were similar to those observed with a clinically
established AT1 receptor antagonist, Losartan. Further, since
Losartan is known to also inhibit EGFR transactivation [6,7],
combination therapy with EGF significantly improved cardiac
recovery more than with each drug alone. Losartan-induced
reduction in EGFR phosphorylation was prevented by co-
administration of EGF implying that rescuing the EGFR
inhibitory effect of AT1 receptor antagonists by co-treatment with
EGF may represent a novel clinical approach to improving cardiac
function in diabetic patients.
In this study our initial goal was to determine whether the
inhibition or activation of erbB2 and EGFR signaling was able to
aid or exacerbate recovery of cardiac function following global
ischemia in isolated hearts from normal or streptozotocin-induced
diabetic rats. We found that chronic inhibition of either EGFR or
erbB2 receptor signaling generally exacerbated recovery from
ischemia-reperfusion injury of hearts isolated from normal and
diabetes (Figures 1 and 2). However, the extent of cardiac
Figure 9. The % change in cardiac function parameters of diabetic (D) hearts treated with EGF (+EGF), Losartan (+Losartan) or their
combination (+Losartan+EGF). The percent change in parameter is calculated relative to the % recovery seen in the respective diabetic (D)
controls and plotted for a) LVEDP; b) Pmax; c) +dp/dt; d) 2dp/dt; and e) coronary flow. * significantly different from D+ Losartan (p,0.05); #
significantly different from D+ EGF (p,0.05).
doi:10.1371/journal.pone.0039066.g009
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39066dysfunction-induced by the inhibitors (Table 1) appeared to be
greater in normal compared to diabetic hearts implying that the
EGFR/erbB2 pro-survival pathway was significantly impaired in
diabetes. Signaling studies confirmed that diabetes is associated
with a reduction in EGFR and erbB2 phosphorylation at multiple
tyrosine residues that appear to be important signalling cues for
downstream effectors such as ERK1/2, p38MAP kinase and AKT
(Figures 1 and 2). The fact that inhibition of erbB2 or EGFR
signalling by AG825 and AG1478 respectively, in the diabetic
heart also led to decreased phosphorylation of their likely
downstream effectors ERK1/2, p38MAP kinase and AKT (see
Figure 3) implied that these signalling molecules are common
downstream effectors for EGFR and erbB signalling which might
arise from a dimerization of these two erbB receptors. Figure 4
provided evidence for the likely dimerization or EGFR and erbB2
in normal and diabetic hearts. Importantly as implied by the
cardiac function studies, compared to normal animals diabetes led
to decreased levels of EGFR/erbB2 dimerization in the heart that
was further reduced upon chronic treatment of animals with either
AG1478 or AG825. The reduced dimerization may partly be
explained by reduced expression of the two receptors in diabetic
hearts as seen in Figures 1 and 2. Thus, our data suggest that
EGFR and erbB2 heterodimerization-mediated signalling via
ERK1/2, p38 MAP kinase and AKT pathways is at play in
diabetic hearts which when chronically inhibited by either
AG1478 or AG825 leads to worsening recovery of hearts from
acute ischemia-reperfusion injury.
We next showed that activation of this pathway by acute
administration of EGF significantly reversed the detrimental
functional and biochemical changes following ischemic injury in
diabetic hearts. Acute administration of EGF either before or after
ischemia led to marked improvements in cardiac function in the
diabetic heart following I/R (Table 2). The EGF-mediated
recovery in cardiac parameters following I/R was generally much
greater in diabetes than in normal hearts (Figure 5) implying the
differential responsiveness of this pathway to ligand-mediated
activation in the healthy and diseased heart. This is not an
unexpected result as the normal heart already has a higher level of
EGFR/erbB2 signaling compared to the diabetic heart where
signaling is severely compromised (see Figures 1 and 2). A further
point of note is that giving EGF after ischemia, rather than before
ischemia, was equally or more effective in improving cardiac
recovery following I/R (Table 2 and Figure 5) thereby implying
that EGF administration even after an ischemic event may
represent a novel therapeutic strategy for improving cardiac
recovery in patients with diabetes.
Our findings that chronic inhibition of EGFR or erbB2
signaling markedly reduces cardiac function recovery following
acute I/R injury in the normal rat heart are supported by other
studies where either chronic [35] or acute [36] pharmacological
inhibition in non-diabetic mice also led to similar conclusions as
well as by recent studies where even acute activation of these
pathways appeared protective in hearts subjected to ischemic stress
[32]. Also chronic pharmacological inhibition of EGFR with
AG1478 or EKB-569 (an irreversible tyrosine kinase inhibitor) or
expression of mutant EGFR or erbB2 led to the development of
cardiac dysfunction in non-diabetic hearts [35]. Here we presented
evidence that further suggests that these pathways are even more
important in diabetes than in normal hearts, a fact that might be
clinically significant. It is already known that cardiac sensitivity of
diabetic patients to some conventional antidiabetic drugs makes
determining the specific treatment for diabetes-and its cardiac
complications more difficult and there is a drive to identify novel
drugs that do not impinge on cardiac function [37]. Our study
highlights that drugs that likely directly or indirectly inhibit erbB
receptor family signalling might more adversely affect cardiac
function and/or cardiac recovery following ischemia. Thus,
diabetic patients might be more sensitive to anticancer therapies
directed at erbB receptors some of which are known to induce
severe cardiac toxicities [23,25,26].
Of the relative contribution of erbB receptor signalling, erbB2
signaling appears to be more critical to cardiac recovery in both
normal and diabetic hearts. This was evidenced from Figures 2
and 3 which show that at the doses used, AG825 or AG1478 gave
similar inhibitions of erbB2 or EGFR phosphorylation respective-
ly, but cardiac recovery in all the parameters studied was generally
worse with AG825 (Table 1). This could also mean that in addition
to signalling via erbB2/EGFR heterodimers, signalling via erbB2/
erbB4 might also be involved, though this was not studied further
here. Nonetheless, both signalling of erbB2 with erbB4 and EGFR
appears to be important in the normal adult heart [27,32].
Figure 10. Acute EGF administration prevented Losartan-
mediated inhibition of EGFR phosphorylation in diabetic
hearts. a) A representative Western blot showing post-I/R levels of
phosphorylated (p-EGFR) and total EGFR (T-EGFR) in diabetic hearts (D)
and following acute administration during reperfusion of Losartan
(LOS), EGF (EGF) or their combination (EGF+LOS) and b) densitometric
histogram quantifying the relative intensity of p-EGFR/t-EGFR following
normalization of each molecule to actin. N=4; * significantly different
to D and ** significantly different to LOS.
doi:10.1371/journal.pone.0039066.g010
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39066Since the impact of cardiac ischemia on phosphorylation of
EGFR and ERB2 as well as their downstream signaling molecules
is not known, we next showed that hearts subjected to ischemia led
to a reduction in EGFR and erbB2 phosphorylation as well as that
of the known downstream effectors, ERK1/2 and p38 MAP
kinases (Figure 6). Additionally, as the AKT/FOXO survival
pathway has recently been shown to be an important survival
signal in ischemia-reperfusion injury [38], we also investigated the
effect of ischemia and EGF administration on this pathway in
normal and diabetic hearts (Figures 6–8). Although other
pathways can reportedly regulate FOXO activity [38,39], the
PI-3 kinase/AKT pathway appears to be important in the heart
where it negatively regulates FOXO activity by increasing FOXO
phosphorylation thereby leading to its inactivation via nuclear
exclusion, polyubiquitination and degradation [29,38]. PI3-
kinase/AKT is a known downstream effector pathway of EGFR
and erbB2 signaling. Consistent with this, we showed that
diabetes-led to an attenuation in EGFR/erbB2/AKT pathway
that was further attenuated upon exposure of hearts to ischemia
and correlated with a worsening recovery of cardiac function
following I/R (Table 2 and Figures 1, 2 and 6). In both normal
and diabetic hearts, ischemia led to decreased phosphorylation of
both AKT and FOXO3a at Ser
253 (Figure 6) whereas acute
administration of EGF, either before or after ischemia, opposed
these ischemia-induced changes in the AKT/FOXO3a pathway
(Figures 7 and 8). Thus our data are consistent with the notion that
ischemia leads to reduced EGFR/erbB2/AKT signaling that is
coupled with a transient activation of FOXO signaling (repre-
sented by decreased phosphorylation at Ser
253) most likely as a
compensatory mechanism to enhance cardiac survival pathways
and inhibit pro-death signaling. However, this transient FOXO
activation appeared to be insufficient in preventing ischemia-
induced cardiac impairment as cardiac function was actually
compromised following I/R. A recent study in cardiomyocytes is
supportive of our finding where hypoxia led to significant
decreases in FOXO protein phosphorylation consistent with its
activation and nuclear localization [30]. Interestingly, administra-
tion of EGF, a specific ligand for EGFR, led to raised levels of
phosphorylated EGFR and that of the ligand-less erbB2 receptor
(Figures 7 and 8), implying the latter’s recruitment into EGFR/
erbB2 heterodimers. This is not an unexpected finding as we
showed above (Figure 4) that diabetes is associated with reduced
EGFR/erbB2 heterodimers and thus appear to be important
signaling partners in cardiac function including following I/R
injury. Further, EGF-mediated activation of EGFR/erbB2/AKT
signaling in the hearts via modulation of FOXO3a activity appears
to be a critical survival pathway in preventing diabetes-mediated
cardiac dysfunction. However, whether these survival pathways
are largely at play within the coronary vasculature and/or cardiac
muscle is not known and requires further study.
Angiotensin II receptor blockers (ARBs) such as Losartan are
clinically established cardioprotective agents in the treatment of
diabetes-induced end-organ damage. However, since Losartan can
also inhibit EGFR transactivation [6,7], we hypothesized that the
Figure 11. Schematic model summarising our findings on the role of EGFR/erbB2 signaling in diabetes-induced cardiac
dysfunction. Diabetes and/or hyperglycemia via attenuation of the EGFR/erbB2 signaling and through subsequent modulation of downstream
effectors such as ERK1/2, p38 MAPK or AKT/FOXO can lead to cardiac dysfunction. The effects of diabetes on EGFR/erbB2 pathway are exacerbated by
blockade of this pathway by AG1478 or AG825 which leads to worsening cardiac recovery from I/R. However, the inhibitory effects of diabetes on
EGFR/ErbB2 pathway may be opposed by administering EGF that also leads to improved cardiac function. The Angiotensin II (Ang II)/AT1 receptor
pathway can also activate EGFR/erbB2 pathway that can be blocked by Losartan. Co-administration of EGF with Losartan attenuates losartan-
mediated EGFR blockade and improves cardiac function in diabetes beyond that attained by either drug alone.
doi:10.1371/journal.pone.0039066.g011
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e39066existing cardioprotective effects of ARBs might not be optimal and
could be improved by preventing their inhibition of the pro-
survival EGFR pathway. Indeed, our results showed that
combination of Losartan with EGF administration after ischemia
significantly improved cardiac recovery more than with each drug
alone (Table 3 and Figure 9). Further, consistent with ARBs
known inhibition of Angiotensin II-mediated transactivation of
EGFR, diabetic hearts treated with Losartan reduced EGFR
phosphorylation compared to untreated diabetes following I/R
(Figure 10). In contrast, combination treatment of Losartan with
EGF, prevented the inhibitory effects of Losartan on EGFR
transactivation as phosphorylation levels were raised to similar
levels as EGF administration alone (Figure 10). A schematic model
summarising our findings on the role of EGFR/erbB2 signaling in
diabetes-induced cardiac dysfunction is given in Figure 11. Our
data may have important clinical implications as they suggest for
the first time that rescuing the EGFR inhibitory effect of AT1
receptor antagonists or diabetes and/or ischemia by activators of
the EGF/EGFR pathway may represent a novel clinical approach
to improve protection against end-organ damage in diabetic
hearts. However, the clinical success of such a strategy may require
targeted cardiac delivery of EGF or its analogues as ligands for
erbB receptors can have other, sometimes unwanted opposing,
effects on different organ systems [9,10,40].
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